Table 2.
Sensitivity analysis of select outcomes post-match
| 6-month baseline period | 12-month post-index period | p value | |||||
|---|---|---|---|---|---|---|---|
| Outcome | Ig-treated, N = 678 | Non-Ig-treated, N = 678 | Ig-treated, N = 678 | Non-Ig-treated, N = 678 | Comparison within Ig-treated | Comparison within non-Ig-treated | Comparison of post-index use between Ig-treated and non-Ig-treated |
| Patients with ≥ 1 level of assistive device deterioration post-index, n (%) | – | – | 37 (5.5) | 49 (7.2) | – | – | 0.1904 |
| Patients with ≥ 2 levels of assistive device deterioration post-index, n (%) | – | – | 36 (5.2) | 49 (7.2) | – | – | 0.1492 |
| Patients with ≥ 1 claim for anticonvulsants, n (%) | 326 (48.1) | 322 (47.5) | 335 (49.4) | 344 (50.7) | 0.4245 | 0.0500 | 0.6075 |
| Patients with anticonvulsant improvement post-index, n (%) | – | – | 59 (18.1) | 52 (16.1) | – | – | 0.5103 |
| Patients with ≥ 1 claim for antidepressants, n (%) | 258 (38.1) | 242 (35.7) | 274 (40.4) | 313 (46.2) | 0.0953 | < 0.0001 | 0.0321 |
| Patients with antidepressant improvement post-index, n (%) | – | – | 38 (14.7) | 20 (8.3) | – | – | 0.0241 |
| Patients with ≥ 1 claim for opioids, n (%) | 259 (38.2) | 270 (39.8) | 287 (42.3) | 338 (49.9) | 0.0444 | < 0.0001 | 0.0035 |
| Patients with opioid improvement post-index (n, %) | – | – | 83 (32.0) | 60 (22.2) | – | – | 0.0110 |
Ig immunoglobulin